S-1: BioLargo Files for 30M Share Offering with Clearthink

BioLargo, Inc. has filed an S-1 registration statement to allow for the resale of up to 30 million shares of its common stock by selling stockholder Clearthink Capital Partners, LLC.

Summary

• BioLargo, Inc. has filed an S-1 registration statement to register for resale up to 30,000,000 shares of its common stock by Clearthink Capital Partners, LLC, a selling stockholder.
• The company has a purchase agreement with Clearthink allowing for up to $10,000,000 in stock purchases, with the purchase price based on a discount to market prices.
• The company will not receive proceeds from the resale of these shares by Clearthink, but may receive up to $10,000,000 in aggregate gross proceeds from future sales to Clearthink.
• Proceeds from any future sales to Clearthink are intended for working capital, research and development, and commercialization of the company's technologies.
• The company's stock is traded on the OTCQX Best Market under the symbol BLGO, with the last reported sale price on April 8, 2026, being $0.15.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly speculative due to the company's recurring losses, negative cash flow, auditor's going concern warning, and ongoing litigation, despite its innovative technology pipeline.

Positives

• The company has secured a purchase agreement with Clearthink Capital Partners, LLC, providing a potential avenue for future capital raises up to $10,000,000.
• The registration statement allows for the resale of up to 30 million shares, indicating a potential for increased liquidity in the market.
• The company is actively developing and commercializing innovative technologies in environmental solutions, water treatment, and energy storage.
• BioLargo has a portfolio of 34 issued patents with an average remaining duration of seven years, providing a foundation for its intellectual property.

Negatives

• The company has incurred significant losses since inception and anticipates continuing to do so, raising substantial doubt about its ability to continue as a going concern.
• The company's financial condition is heavily reliant on the issuance of equity securities, which is dilutive to existing stockholders.
• BioLargo is currently engaged in litigation with its former largest customer, Pooph Inc., which could have material adverse effects on its financial condition.
• The company's internal disclosure controls and procedures over financial reporting are not effective.
• The company's common stock is considered a penny stock, trading on the OTC Markets, which implies a high degree of risk and volatility.

Risks

• The company is currently engaged in litigation with Pooph Inc. and Ikigai Holdings, LLC, which could have material adverse effects on its financial condition and results of operations.
• The company has incurred losses since inception and may continue to incur losses and negative cash flows in the future.
• The company's ability to access capital markets to fund operations could be limited, and failure to raise capital could adversely affect its business.
• The company has a limited operating history, making future results difficult to forecast and any investment highly speculative.
• Some of the company's products may require regulatory approval from the FDA or EPA.
• The company's internal disclosure controls and procedures over financial reporting are not effective.
• The company's common stock is a penny stock that trades on a limited basis, and its stock price may be volatile.
• Trading in the company's common stock is limited, and future sales could depress the stock price.
• The company relies on third-party manufacturers and suppliers, and disruptions could delay or curtail commercialization.
• The company's technology and products may infringe on the patent rights of others, leading to costly litigation.
• The company faces strong competition from established and new competitors in its various market segments.
• The company's future success depends on its ability to retain and attract high-quality personnel, including senior management.
• The company may struggle to manage its growth effectively.
• The company's business operations could be disrupted by various natural or man-made disasters.
• Increased information technology security threats pose a risk to the company's systems and data.
• Economic uncertainty, recession, and global events may adversely affect the company's business and operations.
• The sale or issuance of common stock to Clearthink will cause dilution, and the perception of such sales could cause the stock price to fall.
• The company's common stock is thinly traded and largely illiquid, potentially affecting its ability to obtain future financing.
• The market price of the company's stock is subject to volatility due to numerous factors beyond its control.
• The company's shares are deemed a penny stock, making it difficult to sell previously restricted stock and potentially limiting market liquidity.
• The company will not pay dividends in the foreseeable future, meaning stockholders will only benefit from appreciation in share price.
• The company regularly issues stock or options instead of cash to pay operating expenses, leading to further dilution.
• The company's stockholders face further potential dilution from any new financing, including preferred stock issuances.
• The company's business involves the use, transmission, and storage of confidential information, and failures in safeguarding this information could result in reputational harm.

Future Outlook

The company anticipates continuing to incur losses and negative cash flows for the foreseeable future, requiring ongoing capital raises. Future success depends on commercializing its technologies and achieving profitability. The company expects to use proceeds from sales to Clearthink for working capital, R&D, and commercialization efforts.

Management Comments

• We believe our Cellinity batteries will have features that far surpass comparable lithium-ion batteries, the dominant incumbent technology in the market, including: Increased safety, no runaway fire risks, and a more sustainable design with no rare-earth elements that is capable of being manufactured completely from a domestic supply chain; Ability to charge and discharge completely, with no degradation of performance, ensuring virtually unlimited charge/discharge cycles, and without self-discharge and no out-gassing; and Increased energy efficiency and energy density in comparison to lithium-ion batteries, and a longer useful life expectancy of at least 10 years and expected to be up to 20 years.
• We believe CupriDyne Clean is the number-one performing industrial odor-control product in the market, and that it offers substantial savings to our customers compared with competing products.
• Our management believes that the resolutions of these proceedings will not have a material adverse effect on the Company's financial position, results of operations, or cash flows. However, adverse outcomes could materially impact future financial results.

Industry Context

StockSavvy.ai notes that BioLargo operates in highly competitive and evolving sectors, including environmental remediation (PFAS, odor control), water treatment, and energy storage. The company's focus on innovative, patented technologies positions it to address significant environmental and energy challenges, but it faces substantial competition from larger, well-capitalized players in each segment.

Comparison to Industry Standards

• In the battery energy storage market, BioLargo's Cellinity technology aims to compete with established lithium-ion battery manufacturers like Tesla, CATL, BYD, Panasonic, and LG, which have significantly greater resources.
• For PFAS water treatment, BioLargo's AEC system competes with conventional methods such as granular activated carbon, ion-exchange, and reverse osmosis, offered by companies like Veolia, AECOM, Xylem, and Pentair.
• In industrial odor control, BioLargo's CupriDyne Clean competes with national companies including Weaver Consulting Group, Atmos Technologies, Chemstation, and OMI Industries.

Legal Proceedings

• BioLargo Inc. and ONM Environmental Inc. filed a lawsuit against Pooph Inc. and Ikigai Marketing Works LLC for patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices, and constructive fraud, seeking damages for unpaid royalties and product purchases.
• Pooph Inc. filed a lawsuit against ONM Environmental alleging breach of contract and implied covenant of good faith and fair dealing, seeking damages for ONM's refusal to fill purchase orders while Pooph was in breach of contract.

Related Party Transactions

• CEO Dennis P. Calvert invested $120,000 in a Clyra Medical securities offering on October 22, 2024, receiving a secured promissory note and a warrant. He invested an additional $21,000 on May 5, 2025.
• CEO Dennis P. Calvert invested $100,000 in a Clyra Medical securities offering on March 16, 2026, receiving a promissory note and a warrant.

Stakeholder Impact

• Existing stockholders will experience dilution from the potential sale of up to 30 million shares to Clearthink and from ongoing equity financings.
• The company's financial struggles and potential for continued losses may impact investor confidence and the stock price.
• The ongoing litigation with Pooph Inc. could negatively affect the company's financial results and management's focus.
• The company's reliance on third-party sales channels means its revenue is dependent on the marketing efforts of partners.

Next Steps

• The company may direct Clearthink to purchase shares of its common stock under the Purchase Agreement after the registration statement is declared effective by the SEC.
• Clearthink may resell the registered shares of common stock at prevailing market prices or in negotiated transactions.
• The company will continue to develop and commercialize its technologies in environmental remediation, water treatment, and energy storage.
• The company intends to seek listing on the Nasdaq Stock Market or another national exchange when eligible.

Key Dates

Recommendation

While BioLargo possesses innovative technologies in growing markets, its precarious financial situation, significant operating losses, auditor's going concern warning, and ongoing litigation present substantial risks. The potential capital raise via Clearthink offers a lifeline but also introduces significant dilution. Investors should monitor the resolution of litigation and the company's ability to secure further funding and achieve profitability before considering a more aggressive stance.

Keywords

BioLargo, S-1 Filing, Clearthink Capital Partners, Common Stock Offering, SEC Registration, Dilution, Going Concern, Litigation, PFAS Remediation, Water Treatment, Battery Technology, Odor Control, OTC Markets, Penny Stock